Cancer Prevention Pharmaceuticals, Inc. is developing novel therapeutic agents, diagnostics, and lifestyle recommendations that make possible the treatment of risk factors for cancer. Our clinical focus is in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners.

Publications show all

Cancer Prevention Pharmaceuticals has published 3 articles.

Patents show all

7Applications

Clinical Trials show all

3Phase 23Phase 31Phase 1

SEC Filings show all

D6S-11

Private Funding Events

DateOfferedSoldType
2013-10-31$6,000,000$4,272,500Equity
2011-03-24$2,000,000$550,000Debt
2009-09-01$2,000,000$1,250,000Debt, Option to Acquire, Security to be Acquired

Key Executives

  • Eugene W Gerner
    Director
  • Frank Meyskens
    Director
  • Jeffrey Jacob
    Director
  • Jeffrey E Jacob
    Executive Officer, Director
  • Richard Love
    Director
  • Daniel Donovan
    Director